Twin	twin	O	O	O	O
preterm	preterm	O	O	O	O
neonates	neonates	O	O	O	O
with	with	O	O	O	O
cardiac	cardiac	O	DISEASE	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
related	related	O	O	O	O
to	to	O	O	O	O
lopinavir/ritonavir	lopinavir/ritonavir	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
twin	twin	O	O	O	O
neonates	neonates	O	O	O	O
who	who	O	O	O	O
were	were	O	O	O	O
born	born	O	O	O	O
prematurely	prematurely	O	O	O	O
at	at	O	O	O	O
32	32	O	O	O	O
weeks	weeks	O	O	O	O
of	of	O	O	O	O
gestation	gestation	O	O	O	O
to	to	O	O	O	O
a	a	O	O	O	O
mother	mother	O	O	O	O
with	with	O	O	O	O
human	human	O	O	OTHERS	I
immunodeficiency	immunodeficiency	O	O	OTHERS	I
virus	virus	O	O	OTHERS	I
infection	infection	O	DISEASE	OTHERS	I
.	.	O	O	O	O

One	one	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
twins	twins	O	O	O	O
developed	developed	O	O	O	O
complete	complete	O	O	O	O
heart	heart	O	DISEASE	OTHERS	I
block	block	O	DISEASE	OTHERS	I
and	and	O	O	O	O
dilated	dilated	O	DISEASE	OTHERS	I
cardiomyopathy	cardiomyopathy	O	DISEASE	OTHERS	I
related	related	O	O	O	O
to	to	O	O	O	O
lopinavir/ritonavir	lopinavir/ritonavir	O	O	O	O
therapy	therapy	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
boosted	boosted	O	O	O	O
protease-inhibitor	protease-inhibitor	O	O	O	O
agent	agent	O	O	O	O
,	,	O	O	O	O
while	while	O	O	O	O
the	the	O	O	O	O
other	other	O	O	O	O
twin	twin	O	O	O	O
developed	developed	O	O	O	O
mild	mild	O	O	O	O
bradycardia	bradycardia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

We	we	O	O	O	O
recommend	recommend	O	O	O	O
caution	caution	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
lopinavir/ritonavir	lopinavir/ritonavir	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
immediate	immediate	O	O	O	O
neonatal	neonatal	O	O	O	O
period	period	O	O	O	O
.	.	O	O	O	O

